Aram Andrew Mangasarian
Vorstandsvorsitzender bei TME PHARMA N.V.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bertram Köhler | M | 53 |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 6 Jahre |
| Joseph deBethizy | M | 74 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 8 Jahre |
| Walter Wenninger | M | 86 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Sven Klussmann | M | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 27 Jahre |
| Hubert Birner | M | 57 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Cornelis Alexander Izeboud | M | 53 | 4 Jahre | |
| Olivier Litzka | M | 56 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Maurizio PetitBon | M | 76 | 8 Jahre | |
| Jarl Ulf Birger Jungnelius | M | 73 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 7 Jahre |
| Susan Coles | F | 58 | 3 Jahre | |
| Karen Ophoff | F | - | 23 Jahre | |
| Denis Lucquin | M | 67 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Peter Johann | M | 67 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Ewelina Staniuk | F | - | 6 Jahre | |
| Heike Balzer | M | - | 24 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Iain Peter Murray Buchanan | M | 72 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 8 Jahre |
| Paula Boultbee | F | 65 | 5 Jahre | |
| Robert Marchesani | M | 63 | 4 Jahre | |
| Jan Birger Fredrik Toernell | M | 64 | - | |
| Martine van Vugt | M | 71 | 2 Jahre | |
| Rolf Magnus Björsne | M | 60 | 5 Jahre | |
| Matthias Baumann | M | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 6 Jahre |
| Alain Herrera | M | 74 | 5 Jahre | |
| Anna Belfrage | F | 62 | 4 Jahre | |
| Lennart Christer Jeansson | M | 83 | 2 Jahre | |
| Gregory Weaver | M | 68 | 1 Jahre | |
| Jens-Peter Fürste | M | - | - | |
| Frank Morich | M | 69 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 2 Jahre |
| Thomas Klein | M | - | - | |
| Donald Munoz | M | 56 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 2 Jahre |
| Bryan Jennings | M | - | 1 Jahre | |
| Jenny Sundqvist | F | 53 | - | |
| Tony Gustavsson | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Deutschland | 24 | 72,73% |
| Schweden | 9 | 27,27% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Aram Andrew Mangasarian
- Persönliches Netzwerk
